Strategic Collaboration Among WeDoctor Unknown, Xellar Biosystems, and Jingtop Bio to Advance Multimodal Preclinical Models for Microbiome Industrialization
Xbiome
AI Drug Developer for Gut Microbiota
Xellar Biosystems
Drug Discovery Service Provider
Recently,Xbiome, Xellar Biosystems, GnotobioSign Strategic Cooperation AgreementThe three parties will take this strategic cooperation as an opportunity, leverage their respective technological advantages to develop more efficient preclinical evaluation models, and jointly promote the construction and commercial development of organ-on-a-chip in microbiological drug research and related technology service platforms.
Figure: Scene of the Tripartite Signing Ceremony
According to the agreement, Xellar Biosystems will combine its expertise in organ-on-a-chip, AI disease modeling, drug testing, and development with Gnotobio's industry-leading integrated experimental animal platform. Leveraging Xbiome’s strengths in microbiome drug development and consumer product innovation, the three parties will jointly explore and develop more accurate preclinical models to advance innovative projects related to the human microbiome.These projects will involve multiple R&D fields such as target validation, preclinical toxicology and efficacy studies, and strain screening, achieving the dual goals of scientific research and commercialization.
Through this collaboration, Xellar Biosystems will start with gut-on-a-chip to develop multiple models for studying the role of the "microbiota-gut-brain axis" in gut function, neural function, and neurological diseases, while further exploring the mechanisms of microbiota and tumor organoids. At the same time, Xellar Biosystems and Xbiome will collaborate on organ-on-a-chip and gut microbiota in areas such as personalized medicine and consumer products, conducting comprehensive commercial exploration in both serious medical treatment and consumer healthcare.
Dr. Xie Xin, Co-founder and CEO of Xellar BiosystemsWe are pleased to collaborate with Xbiome and Gnotobio to explore the application of preclinical models, such as organ-on-a-chip, in the development of gut microbiota drugs and consumer products. As one of China's leading microecological drug companies, Xbiome has made significant advances in AI drug discovery, microbial technology, bioinformatics, and synthetic biology. Gnotobio is one of China’s premier comprehensive animal model platforms, and we look forward to accelerating the commercial application of organ-on-a-chip technology in this field through our partnership.
Tang Yan, Ph.D., Co-founder and CEO of XbiomeXellar Biosystems has deep technical accumulation and capabilities in combining organ-on-a-chip with AI, and has gathered the world's top teams from both the R&D and industrial ends of organ chip technology. Gnotobio is an important strategic layout by Xbiome to build an AI microbiome research and industrial transformation platform. We believe that the deep integration of AI microbiome + organ-on-a-chip + animal models will provide comprehensive solutions with greater commercial value for both the microbiome healthcare and consumer products industries.
Gnotobio General Manager Daoqiang ZhuangRepresentatives: Xellar Biosystems and Xbiome are among the leading teams in China in the fields of organ-on-a-chip + AI and microbiome technology + AI, respectively. We are honored to collaborate with them to advance the integration of animal models and organ-on-a-chip technologies, providing a new generation of solutions for the development and evaluation of microbial agents.
| About Xbiome
Xbiome Co. Ltd., founded in 2017, owns a leading AI microbiome research and industrial transformation platform, strategically focusing on FMT, drug discovery, and probiotics. In drug discovery, the team has completed layouts in fields such as oncology, digestive diseases, immune-related diseases, and urological diseases, with four pipelines entering clinical stages, two of which are in Phase II clinical trials. Regarding FMT, Xbiome has collaborated with nearly 20 well-known tertiary hospitals in China, including Peking University Cancer Hospital and Peking Union Medical College Hospital, to conduct gut microbiome clinical research across various indications. Additionally, it has developed the T-FMT personalized precision gut microbiome treatment project, targeting the broader health market to benefit patients with chronic conditions and sub-health populations. In the probiotics field, Xbiome has successfully completed commercial collaborations and transformations with several top domestic and international health companies while continuously advancing the development of proprietary strains.
| About Xellar Biosystems
Xellar Biosystems was founded in Boston, USA, at the end of 2021. It is the world’s first "3D-Wet-AI" biotech startup to leverage organ-on-a-chip technology combined with high-content three-dimensional (3D) cell imaging, computer vision (CV), and artificial intelligence (AI) for drug discovery and precision medicine research. The founding team of Xellar comprises members mostly from renowned multinational biopharmaceutical companies and top academic institutions such as Harvard University and MIT, bringing extensive experience in pharmaceutical product development and cutting-edge bio-AI technology research. Xellar Biosystems is the only organ-on-a-chip company globally that is collaborating with the FDA and multinational pharmaceutical alliances to co-develop the next generation of preclinical drug efficacy testing standards based on organ-on-a-chip technology. Xellar Biosystems has established strategic and research collaborations with multiple biopharmaceutical companies and academic institutions.
| About Gnotobio
Gnotobio was founded in October 2019 by industrial and academic experts in the fields of microbiome research and germ-free animal research in China. As a biotechnology company specializing in the breeding and production of germ-free animals and outsourcing services for animal experiments, it provides disease animal models, drug screening models, germ-free experimental animals, and related services to research institutions, hospitals, pharmaceutical companies, etc., continuously developing into a comprehensive experimental animal platform company.
-End-